TY - JOUR
T1 - The Hepatitis C Virus Care Continuum
T2 - Linkage to Hepatitis C Virus Care and Treatment Among Patients at an Urban Health Network, Philadelphia, PA
AU - Coyle, Catelyn
AU - Moorman, Anne C.
AU - Bartholomew, Tyler
AU - Klein, Gary
AU - Kwakwa, Helena
AU - Mehta, Shruti H.
AU - Holtzman, Deborah
N1 - Funding Information:
Received August 1, 2018; accepted December 20, 2018. Supported by the Centers for Disease Control and Prevention (hepatitis C virus grant CDC-RFA-PS12-1209PPHF12); Frontlines of Communities in the United States, a program of Gilead Sciences, Inc.; and the National Institutes of Health (training grant T32AI102623, to C.C.). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or Gilead Sciences, Inc. © 2019 by the American Association for the Study of Liver Diseases. View this article online at wileyonlinelibrary.com. DOI 10.1002/hep.30501
Funding Information:
The authors thank the medical staff and patients at Mary Howard Health Center, PHMC Care Clinic, Health Connection, Congreso Health Center, and Rising Sun Health Center for making this study possible. The authors also thank Grace Lee from the National Nurse-Led Care Consortium for extracting the data from the electronic health records. Finally, the authors thank Kristine Gonnella from the National Nurse-Led Care Consortium for programmatic support and advocating for the extension of the project.
Publisher Copyright:
© 2019 by the American Association for the Study of Liver Diseases.
PY - 2019
Y1 - 2019
N2 - Improving care and treatment for persons infected with hepatitis C virus (HCV) can reduce HCV-related morbidity and mortality. Our primary objective was to examine the HCV care continuum among patients receiving care at five federally qualified health centers (FQHCs) in Philadelphia, PA, where a testing and linkage to care program had been established. Among the five FQHCs, one served a homeless population, two served public housing residents, one served a majority Hispanic population, and the last, a “test and treat” site, also provided HCV treatment to patients. We analyzed data from electronic health records of patients tested for HCV antibody from 2012 to 2016 and calculated the percentage of patients across nine steps of the HCV care continuum ranging from diagnosis to cure. We further explored factors associated with successful patient navigation through two steps of the continuum using multivariable logistic regression. Of 885 chronically infected patients, 92.2% received their RNA-positive result, 82.7% were referred to an HCV provider, 69.4% were medically evaluated by the provider, 55.3% underwent liver disease staging, 15.0% initiated treatment, 12.0% completed treatment, 8.7% were assessed for sustained virologic response (SVR), and 8.0% achieved SVR. Regression results revealed that test and treat site patients were significantly more likely to be medically evaluated (adjusted odds ratio [aOR], 2.76; 95% confidence interval [CI], 1.82-4.17) and to undergo liver disease staging (aOR, 1.92; 95% CI, 1.02-2.86) than patients at the other FQHCs combined. Conclusion: In this US urban setting, over two thirds of HCV-infected patients were linked to care; although treatment uptake was low overall, it was highest at the test and treat site; scaling up treatment services in HCV testing settings will be vital to improve the HCV care continuum.
AB - Improving care and treatment for persons infected with hepatitis C virus (HCV) can reduce HCV-related morbidity and mortality. Our primary objective was to examine the HCV care continuum among patients receiving care at five federally qualified health centers (FQHCs) in Philadelphia, PA, where a testing and linkage to care program had been established. Among the five FQHCs, one served a homeless population, two served public housing residents, one served a majority Hispanic population, and the last, a “test and treat” site, also provided HCV treatment to patients. We analyzed data from electronic health records of patients tested for HCV antibody from 2012 to 2016 and calculated the percentage of patients across nine steps of the HCV care continuum ranging from diagnosis to cure. We further explored factors associated with successful patient navigation through two steps of the continuum using multivariable logistic regression. Of 885 chronically infected patients, 92.2% received their RNA-positive result, 82.7% were referred to an HCV provider, 69.4% were medically evaluated by the provider, 55.3% underwent liver disease staging, 15.0% initiated treatment, 12.0% completed treatment, 8.7% were assessed for sustained virologic response (SVR), and 8.0% achieved SVR. Regression results revealed that test and treat site patients were significantly more likely to be medically evaluated (adjusted odds ratio [aOR], 2.76; 95% confidence interval [CI], 1.82-4.17) and to undergo liver disease staging (aOR, 1.92; 95% CI, 1.02-2.86) than patients at the other FQHCs combined. Conclusion: In this US urban setting, over two thirds of HCV-infected patients were linked to care; although treatment uptake was low overall, it was highest at the test and treat site; scaling up treatment services in HCV testing settings will be vital to improve the HCV care continuum.
UR - http://www.scopus.com/inward/record.url?scp=85063425836&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063425836&partnerID=8YFLogxK
U2 - 10.1002/hep.30501
DO - 10.1002/hep.30501
M3 - Article
C2 - 30633811
AN - SCOPUS:85063425836
SN - 0270-9139
VL - 70
SP - 476
EP - 486
JO - Hepatology
JF - Hepatology
IS - 2
ER -